Rapid Therapeutic Science Laboratories, Inc. (RTSL)

Get Top Rated Stock Alerts Active Traders Depend On

Sign Up Today For FREE News Driven Alerts

Rapid Therapeutic Announces Completion of New ISO 13485 Laboratory

Dallas, TX –  August 18, 2020 – Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver cannabinoid compounds, such as CBD, CBG, and CBN, announces its new ISO 13485 laboratory is ready to begin manufacturing the Company’s new consumer-focused, nhāler brand.

 

Chairman and CEO, Donal R. Schmidt, Jr. stated, “Our new laboratory allows RTSL to produce up to 2.9 million nhāler and RxoidTM MDI per year. In addition, as demand increases, we can scale it to double the output with minimal additional personnel or capital outlay in about 9-12 weeks. It also reduces our manufacturing expenses and is a key process to eventual FDA approval of our MDI product line. Certainly, as we produce other aerosolized products in the future such as prescription medication, we will need this lab. I want to congratulate our team for getting the build-out finished on time and under budget.”

 

Sean Berrier, SVP mentions “RTSL now owns a state-of-the-art lab that complies with FDA guidelines for manufacturing class II medical devices. To my knowledge, no one in the CBD space has a lab of this quality. In the end, our product is about helping people and this lab assures RTSL manufactures safe MDI in a controlled environment so that consumers have absolute trust in our existing and future product lines.”

 

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

 

RTSL has developed and perfected a new method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formulae consisting of one or more cannabinoid compounds, such as CBD, CBG, and/or CBN.  The Company’s RxoidTM and nhāler product lines are manufactured in compliance with Good Manufacturing Practices (GMP), on FDA-listed equipment. Note that while cannabinoids such as CBD, CBG and CBN are not yet approved by the FDA, under the laws of Texas and of many other states, it is legal to consume, sell and export them to legal jurisdictions.

 

Properly formulated MDI deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is the most efficient delivery method for an API other than an IV. In addition, MDIs are less expensive than any other route of delivery, based on the net cost per bioactive mg as tested in blood serum levels. However, MDIs are expensive to formulate and difficult to manufacture in order to deliver cannabinoid compounds to the level required by the FDA and FTC truth in labelling laws.  Ideally, a properly formulated, properly manufactured MDI containing cannabinoids will deliver exactly the same dose on its first use as well as its 100th use.

 

RTSL’s MDIs are a safe and technically superior replacement for vape pens, mods and all-in-one products because they use no heat, function perfectly without using dangerous ingredients, and deliver a 98% bioavailable dose of CBD and/or cannabinoids directly to the systemic blood stream. This allows RTSL to manufacture a scientifically sound and superior alternative to all other cannabinoid vaping systems in a market estimated to be $5 billion in annual sales.

 

RTSL will market nhāler through digital marketing campaigns and RxoidTM products will continue to be sold directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders.  nhāler can be purchased online at www.nhaler.com.  RxoidTM can be purchased by consumers online, at www.rxoid.com. RTSL also produces white label products for select commercial clients.

 

We encourage all individuals to do their own research regarding cannabinoids, the use of MDI and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure, or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).

 

Visit our corporate website at www.rtslco.com.

 

Forward-Looking Statements

 

This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

 

Contact:
Donal (Don) R. Schmidt, Jr.
Chairman and CEO
info@rtslco.com

Phone: 800-497-6059

Fax: 877-676-8527

 

Source: Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Science Laboratories (RTSL), Inc. engages Ezzey Digital Marketing Agency to Launch its New Lifestyle Brand “nhāler”

Dallas, TX – August 6, 2020 – Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) a SEC fully-reporting, growth-oriented manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver aerosolized cannabinoids, such as CBD, CBG, and CBN, announces its relationship with Ezzey Digital Marketing Agency to launch its new proprietary aerosol inhaler and lifestyle brand to be called nhāler.

 

RTSL digital infrastructure built by Ezzey – Over the last 90 days Ezzey has been engaged in the first phase of creating & building the core digital marketing infrastructure for RTSL and their product brands.

 

During this initial phase, the RTSL brand strategy and expansion plans were analyzed and optimized.  One of the first tasks at hand was to identify the audiences that were targeted to be served and make sure the product brands were in alignment. In this critically important step, Ezzey and RTSL decided to create a lifestyle brand that appealed to the mass audiences that were looking for solutions to help them to alleviate those symptoms that most people have…stress, tiredness, and lack of ability to focus.  As a result, a new product brand called nhāler was created with a scheduled launch date of August 17, 2020. On this date, RTSL will make its first three-line extensions available to the public. nhāler can be purchased at www.nhaler.com.

 

Rapid Therapeutic Science Laboratories, Inc. Chairman and CEO, Donal R. Schmidt, Jr. stated, “in an industry where it is critically important to have a competitive edge, Ezzey provides the necessary knowledge, skills, and abilities to help RTSL set themselves apart by building a solid foundation with expansion plans.”  Mr. Schmidt continued, “we are able to pull from Ezzey’s deep experience in creating, launching, and scaling brands such as Bebe, Estee Lauder, Honda Motor Company, Juul/PAX, Pfizer Pharmaceuticals, Simple Human, Target, Victoria’s Secret, and Warner Brothers.”

 

Ezzey Digital Marketing President & Co-Founder, Ross Denny stated, “it is through the successful execution that you get results.  One of the top priorities is the execution of a marketing plan that maintains complete alignment with RTSL production plans. As the RTSL manufacturing capacity increases, our plan is built to scale with increased demand”.

 

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

 

RTSL has developed and perfected a new method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formulae consisting of one or more cannabinoid compounds, such as CBD, CBG, and/or CBN.  The Company’s RxoidTM and nhāler product lines are manufactured in compliance with GMP, on FDA listed equipment. Note that while cannabinoids such as CBD, CBG and CBN are not yet approved by the FDA, under the laws of Texas and of many other states, it is legal to consume, sell and export them to legal jurisdictions.

 

Properly formulated MDI deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is the most efficient delivery method for an API other than an IV. In addition, MDI are less expensive than any other route of delivery, based on the net cost per bioactive mg as tested in blood serum levels. However, MDI are expensive to formulate and difficult to manufacture in order to deliver cannabinoid compounds to the level required by the FDA and FTC truth in labelling laws.  Ideally, a properly formulated, properly manufactured MDI containing cannabinoids will deliver exactly the same dose on its first use as well as its 100th use.

 

RTSL’s MDI are a safe and technically superior replacement for vape pens and other products because they use no heat, function perfectly without using dangerous ingredients, and deliver a 98% bioavailable dose of CBD and/or cannabinoids directly to the systemic blood stream. This allows RTSL to manufacture a scientifically sound and superior alternative to all other cannabinoid delivery systems in a market estimated to be $5 billion in annual sales.

 

RTSL will market nhāler through digital marketing campaigns and RxoidTM products will continue to be sold directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders.  RxoidTM can be purchased by consumers online, at www.rxoid.com.

 

We encourage all individuals to do their own research regarding cannabinoids, the use of MDI and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure, or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).

 

Visit our corporate website at www.rtslco.com.

 

Forward-Looking Statements

This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

 

Contact:
Donal (Don) R. Schmidt, Jr.
Chairman and CEO
info@rtslco.com

Phone: 800-497-6059

Fax: 877-676-8527

 

Source: Rapid Therapeutic Science Laboratories, Inc.

 

Rapid Therapeutic Science Files with FDA to Register Facility and Products

Dallas, TX –  August 4, 2020 – Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver aerosolized cannabinoids, such as CBD, CBG, and CBN, announces that it has formally engaged FDA Compliance Solutions, LLC to begin the initial FDA regulatory process of registering their new facilities and ultimately all products. FDA Compliance Solutions, LLC will act as RTSL’s agent through the entire registration process. FDA Compliance Solutions submitted RTSL’s initial filing required by the FDA in May 2020.

 

This registration process will establish the initial account and fulfill preliminary FDA compliance notification requirements by documenting current domestic manufacturing locations, and product offerings in the secure approved FDA electronic directory database for all products in commercial distribution in the United States. Registration will incorporate presentation of associated product advertising and labeling (exterior packaging, instructions for use, websites, and promotional materials).

 

Donal R. Schmidt, Jr., CEO states “We look forward to having our facilities and products fully registered. This will ensure our products adhere to the highest standards of safety and efficacy as required by the FDA for any type of medical product being sold in the US or abroad. Except for our cannabinoids, all our consumables and excipients are already listed in Drug Master Files (DMF) with the FDA. This is the first step in ultimately obtaining a fully compliant product in the anticipated regulatory environment related to cannabinoids. By seeking registration in conjunction with our new ISO 13485 manufacturing laboratory facility, we are leading the cannabinoid space in the standards that the rest of the medical world utilizes.”

 

This effort will lay the introductory groundwork for full implementation of cGMP (current Good Manufacturing Practices) operational control. These regulations have the force of law (Quality System Regulation – 21 CFR 820 – 06/01/97), with the primary intent of ensuring provision of safe, pure, and effective products. Rapid Therapeutics’ goal of delivering quality products, while safeguarding the health of our many consumers remains the highest priority.

 

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

 

RTSL has developed and perfected a new method of formulating and manufacturing pressurized metered dose inhalers (pMDI or MDI) that contain and properly aerosolize proprietary formulae consisting of one or more cannabinoid compounds, such as CBD, CBG, and/or CBN which may or may not be blended with or without terpenes). The Company’s RxoidTM product line is manufactured in compliance with GMP, on FDA approved equipment. Note that while non-THC cannabinoids such as CBD and CBG are not yet approved by the FDA, under the laws of Texas and of many other states, it is legal to consume, sell and export them to legal jurisdictions.

 

Properly formulated MDI deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is generally the most efficient delivery method for an API other than an IV. In addition, MDI are less expensive than any other route of delivery, based on the net cost per bioactive mg as tested in blood serum levels. MDI are, however, expensive to formulate and difficult to manufacture to deliver cannabinoid compounds to the level required by the FDA and FTC truth in labelling laws. Ideally, a properly formulated, properly manufactured MDI containing cannabinoids will deliver the same dose on its first use as well as its 100th use.

 

RTSL’s MDI are a safe and technically superior replacement for vape pens because they use no heat, function perfectly without using dangerous ingredients, and deliver a 98% bioavailable dose of CBD and/or CBG or CBN directly to the systemic blood stream. This allows RTSL to address the current U.S. vape market, which is estimated to be $5 billion in annual sales.

 

RTSL markets its RxoidTM MDI products directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders as well as chronic pain and insomnia. RTSL’s MDI products also can be purchased by consumers online, at www.rxoid.com.

 

We encourage all individuals to do their own research regarding cannabinoids, the use of MDI and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure, or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).

 

Visit our corporate website at www.rtslco.com.

 

Forward-Looking Statements

 

This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

 

Contact: Donal (Don) R. Schmidt, Jr. Chairman and CEO info@rtslco.com
Phone: 800-497-6059
Fax: 877-676-8527

 

Source: Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Completes Delivery of Additional 6,000 Units of its Proprietary Metered Dose Inhalers

Dallas, TX –  July 14, 2020 – Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver aerosolized cannabinoids, such as CBD, CBG, and THC, announced today that it has delivered an additional 6,000 units (8,000 total) under its previously announced 100,000 unit order that was recently expanded to 250,000 units.

 

The Company has leased a state-of-the-art lab tested to ISO 6 standards and maintains general facility/process controls in its environmentally filtered operations, as part of compliance with FDA Good Manufacturing Practices (GMP) related to ISO 13485.  This lab will allow the company to pursue RTSL’s stated goal of FDA registration of all RTSL products.

 

Rapid Therapeutic Science Laboratories, Inc. Chairman and CEO, Donal R. Schmidt, Jr. stated, “This 6,000-unit lot was the last production run before we relocated to our new ISO 13485 lab. Our new lab allows us to manufacture a higher-quality product more quickly, and with less waste than we could previously.”

 

Mr. Schmidt continued, “With an estimated gross margin of approximately $20 per unit, this order for 250,000 units, by itself, could represent up to $5,000,000 in gross profit for the Company.  Our RxoidTM CBD Inhalers are currently being sold through doctors’ offices and in pharmacies across the United States.”

 

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

 

RTSL has developed and perfected a new method of formulating and manufacturing pressurized metered dose inhalers (pMDIs) that contain and properly aerosolize proprietary formulae consisting of one or more cannabinoid compounds, such as CBD, CBG, and/or THC (only sold where legal).  The Company’s RxoidTM product line is manufactured in compliance with cGMP, on FDA approved equipment. Note that while non-THC Cannabinoids such as CBD and CBG are not yet approved by the FDA, under the laws of Texas and of many other states, it is legal to consume, sell and export them to legal jurisdictions.

 

Properly formulated MDIs deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is the most efficient delivery method for an API other than an IV. In addition, MDIs are less expensive than any other route of delivery, based on the net cost per bioactive mg as tested in blood serum levels. MDIs are, however, expensive to formulate and difficult to manufacture in order to deliver cannabinoid compounds to the level required by the FDA and FTC truth in labelling laws.  Ideally, a properly formulated, properly manufactured MDI containing cannabinoids will deliver exactly the same dose on its first use as well as its 100th use.

.

RTSL’s MDIs are a safe and technically superior replacement for vape pens, because they use no heat, function perfectly without using dangerous ingredients, and deliver a 98% bioavailable dose of CBD and/or THC directly to the systemic blood stream. This allows RTSL to address the current U.S. vape market, which is estimated to be $5 billion in annual sales.

 

RTSL markets its RxoidTM MDI products directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders.  RTSL’s MDI products also can be purchased by consumers online, at www.rxoid.com.

 

We encourage all individuals to do their own research regarding cannabinoids, the use of MDIs and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure, or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).

 

Visit our corporate website at www.rtslco.com.

 

Forward-Looking Statements

This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

 

Contact:
Donal (Don) R. Schmidt, Jr.
Chairman and CEO
info@rtslco.com

Phone: 800-497-6059

Fax: 877-676-8527

 

Source: Rapid Therapeutic Science Laboratories, Inc.

 

Rapid Therapeutic Announces Major Contract is Increased by 150% to 250,000 Metered Dose Inhalers

Dallas, TX – July 9, 2020  – Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL), a fully-reporting, early stage, emerging biotech company focused on aerosol delivery of cannabinoids in the legal hemp and cannabis space using Metered Dose Inhalers (MDIs), announced today that RTSL has received an additional commitment of 150,000 units under a 100,000 unit wholesale order of its RxoidTM brand 5.0 mg proprietary CBD/CBG formulation which delivers a 98% bioavailable dose of CBD directly to the systemic blood stream.

 

Donal R. Schmidt, Jr., Chairman and CEO stated, “Our customer that specializes in sales directly to health practitioners has increased their commitment from 100,000 to 250,000 units. The primary reason given was the quality and relief their clients’ patients were receiving from our product. Undoubtedly, our customer clients see the efficacy and value of our delivery method for a pure, clean product. All of these orders will be built in our new ISO 13485 compliant facility. Physicians understand the importance of this lab and it is being reflected in their view of our product.”

 

Mr. Schmidt continued, “Our RxoidTM CBD Inhalers are currently being sold through doctors’ offices and in pharmacies across the United States and we are extremely pleased about our products’ acceptance throughout the medical community. I expect this trend will continue to expand as word spreads about the quality of our products and our compliance with GMP standards.”

 

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

 

RTSL has developed and perfected a new method of formulation and manufacturing to deliver pure CBD, CBG and/or THC and combinations thereof in legal jurisdictions to consumers through an FDA approved medical device known as a metered dose inhaler (MDI). The RxoidTM MDI product line is manufactured in compliance with cGMP on FDA approved equipment. Non-THC Cannabinoids are not yet approved by the FDA but are legal to consume in TX and many other states and export to legal foreign jurisdictions.

 

Properly formulated MDIs deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is the most efficient method of delivery of an API other than an IV. RTSL’s MDIs are a safe replacement for vape pens and delivers a 98% bioavailable dose of CBD and/or THC directly to the systemic blood stream. The current vape market in the US is estimated to be $5 Billion.

 

An MDI is the replacement for vape pens as it uses no heat and needs no dangerous ingredients to work. In addition, MDIs are less expensive than any other route of delivery measured by blood serum levels. They are however, expensive to formulate and manufacture, in order to legally and properly work as an MDI under FTC rules on truth and labeling.

 

RTSL markets its RxoidTM MDI products directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders.

 

RTSL’s MDI products also can be purchased online at www.rxoid.com.

 

We encourage all customers to do their own research regarding cannabinoids, the use of MDI’s and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).

 

Visit our corporate website at www.rtslco.com.

 

Forward-Looking Statements

This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

 

Contact:
Donal (Don) R. Schmidt, Jr.
Chairman and CEO
investor@rtslco.com

Source: Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Completes Initial Delivery of 2,000 Units of its Proprietary Metered Dose Inhalers

Dallas, TX –  July 8, 2020  – Rapid Therapeutic Science Laboratories, Inc. (OTCPK: RTSL), a SEC fully-reporting, growth-oriented company focused on manufacturing and marketing aerosol delivery systems based on pressurized Metered Dose Inhaler (MDI) technology, announced today that it has delivered an initial 2,000 units under its previously announced 100,000 unit order.

 

Rapid Therapeutic Science Laboratories, Inc. Chairman and CEO, Donal R. Schmidt, Jr. stated, “RTSL is moving forward on its first major wholesale contract. We have completed the first shipment totaling 2,000 units of our proprietary CBD/CBG formula under our white label order of 100,000 units we previously announced. These MDIs are currently being sold through doctors’ offices and in pharmacies across the United States. The initial lot of 2,000 was presold by our customer before we manufactured them. We will continue to manufacture and ship under this order as we discuss additional white label opportunities with other distributors. This first shipment demonstrates our ability to deliver large unit orders on a timely basis while preserving product quality.”

 

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

 

RTSL is an aerosol manufacturer which has developed and perfected a new method of formulation and manufacturing to deliver pure CBD, CBG and/or THC and combinations thereof in legal jurisdictions to consumers through an FDA approved medical device known as a pressurized Metered Dose Inhaler (pMDI or MDI). The Rxoid MDI product line is manufactured in compliance with GMP on FDA approved equipment. Non-THC Cannabinoids are not yet approved by the FDA but are legal to consume in TX and many other states and export to legal foreign jurisdictions.

 

An MDI is a replacement for vape pens, as it uses no heat and needs no dangerous ingredients to work. In addition, MDIs are less expensive than any other delivery method, measured by blood serum levels. They are however, expensive to formulate and manufacture, in order to legally and properly work as an MDI under FTC rules on truth and labeling.

 

RTSL markets its RxoidTM MDI products directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders.

 

RTSL’s MDI products also can be purchased by consumers online at www.rxoid.com.

 

We encourage all customers to do their own research regarding cannabinoids, the use of MDIs and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).

 

Visit our corporate website at www.rtslco.com.

 

Forward-Looking Statements

This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

 

Contact:
Donal (Don) R. Schmidt, Jr.
Chairman and CEO
info@rtslco.com

Phone: 800-497-6059

Fax: 877-676-8527

 

Source: Rapid Therapeutic Science Laboratories, Inc.

 

Rapid Therapeutic Enters Contract for Certified Lab for Manufacturing Consistent with FDA Rules

Dallas, TX – June 30, 2020 – Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented company focused on manufacturing and marketing aerosol delivery systems based on pressurized Metered Dose Inhaler (MDI) technology, announced today that it has executed a contract leasing a new state-of-the-art laboratory.  The laboratory is being certified for manufacturing under Food and Drug Administration (FDA) rules.

 

Rapid Therapeutic Science Laboratories, Inc. Chairman and CEO, Donal R. Schmidt, Jr. stated, “We are extremely pleased to announce the Company has leased a state-of-the-art lab tested to ISO 6 standards. This lab will allow us to immediately pursue RTSL’s stated goal of FDA registration of all RTSL products. RTSL will immediately begin manufacturing according to ISO 13485 standards for medical devices.” https://www.iso.org/iso-13485-medical-devices.html. https://www.iso.org/standard/59752.html. The FDA adopted this standard in 2018. https://www.iso.org/news/ref2318.html.

 

Sean Berrier, Sr. VP and Co-founder commented: “RTSL will not maintain the lab as a certified “clean room,” instead the Company maintains general facility/process controls in its environmentally filtered operations, as part of compliance with FDA Good Manufacturing Practices (GMP) related to ISO 13485.  Nevertheless, RTSL will periodically perform random testing to assess initial set-up, filter functional efficacy, personnel gowning consistency, and general process stability. Under ISO 13485 the lab rooms will function as “control rooms.” The goal is to organize layout, and minimize overhead particulate matter, thereby optimizing process flow and reducing product fallout. This allows for RTSL to manufacture a class II medical device under GMP. We believe we are one of only a handful of companies manufacturing CBD consumer products with this level of sophistication. This lab gives our clients a high level of assurance that our products are safe and clean with no adulterations.”

 

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

 

RTSL is an aerosol manufacturer which has developed and perfected a new method of formulation and manufacturing to deliver pure CBD, CBG and/or THC and combinations thereof in legal jurisdictions to consumers through an FDA approved medical device known as a pressurized Metered Dose Inhaler (pMDI or MDI). The Rxoid MDI product line is manufactured in compliance with GMP on FDA approved equipment. Non-THC Cannabinoids are not yet approved by the FDA but are legal to consume in TX and many other states and export to legal foreign jurisdictions.

 

A MDI is a replacement for vape pens, as it uses no heat and needs no dangerous ingredients to work. In addition, MDIs are less expensive than any other route of delivery measured by blood serum levels. They are however expensive to formulate and manufacture so that they legally and properly work as an MDI under FTC rules on truth and labeling.

 

RTSL markets its RxoidTM MDI products directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders.

 

RTSL’s MDI products also can be purchased by consumers online at www.rxoid.com.

 

We encourage all customers to do their own research regarding cannabinoids, the use of MDIs and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).

 

Visit our corporate website at www.rtslco.com.

 

Forward-Looking Statements

This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

 

Contact:
Donal (Don) R. Schmidt, Jr.
Chairman and CEO
info@rtslco.com

Phone: 800-497-6059

Fax: 877-676-8527

 

Source: Rapid Therapeutic Science Laboratories, Inc.

 

Rapid Therapeutic Announces Record Order for 100,000 Units of its Metered Dose Inhalers Addressing $9.3 Billion CBD Market

Rapid’s RxoidTM branded inhalers deliver 98% bioavailable dose of CBD utilizing proprietary formulation blend

 

Dallas, TX – June 23, 2020  – Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL), a fully-reporting, early stage, emerging biotech company focused on manufacturing and marketing aerosol delivery of cannabinoids, including CBD, in the legal hemp and cannabis space using Metered Dose Inhalers (MDIs), announced today that RTSL received an order for a 100,000 unit wholesale order of its RxoidTM brand 5.0 mg proprietary CBD/CBG formulation which delivers a 98% bioavailable dose of CBD directly to the systemic blood stream.

 

Donal R. Schmidt, Jr., Esq., Chairman and CEO stated, “Our RxoidTM CBD Inhalers are currently being sold through doctors’ offices and in pharmacies across the United States and we are extremely pleased about our products’ acceptance throughout the medical community.”

 

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

 

RTSL has developed and perfected a new method of formulation and manufacturing to deliver pure CBD, CBG and/or THC and combinations thereof in legal jurisdictions to consumers through an FDA approved medical device known as a metered dose inhaler (MDI). The RxoidTM MDI product line is manufactured in compliance with cGMP on FDA approved equipment. Non-THC Cannabinoids are not yet approved by the FDA but are legal to consume in TX and many other states and export to legal foreign jurisdictions.

 

Properly formulated MDIs deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is the most efficient method of delivery of an API other than an IV. RTSL’s MDIs are a safe replacement for vape pens and delivers a 98% bioavailable dose of CBD and/or THC directly to the systemic blood stream. The current vape market in the US is estimated to be $5 Billion.

 

An MDI is the replacement for vape pens as it uses no heat and needs no dangerous ingredients to work. In addition, MDIs are less expensive than any other route of delivery measured by blood serum levels. They are however expensive to formulate and manufacture so that they legally and properly work as an MDI under FTC rules on truth and labeling.

 

RTSL markets its RxoidTM MDI products directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders.

 

RTSL’s MDI products also can be purchased online at www.rxoid.com.

 

We encourage all customers to do their own research regarding cannabinoids, the use of MDI’s and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).

 

Visit our corporate website at www.rtslco.com.

 

Forward-Looking Statements

This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

 

Contact:
Donal R. Schmidt, Jr., Esq.
Chairman and CEO
investor@rtslco.com

Source: Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Explores Treatment of Anxiety Utilizing Proprietary Delivery System for Psilocybin and CBD

Dallas, Texas – June 10, 2020 –   Rapid Therapeutic Science Laboratories, Inc. (OTCPK: RTSL) (the “Company” or “RTSL”), a fully-reporting company with the U.S. Securities and Exchange Commission, is an innovative biotech company specializing in aerosol delivery of cannabinoids to the systemic blood stream though the pulmonary route of administration. RTSL manufacturers white label products as well as its own branded metered dose inhalers (MDI) under the RxoidTM name using proprietary blends of pure cannabinoids such as CBD and/or CBG. CBD is legal for human consumption in Texas and many other states and foreign countries. RTSL is also testing CBN blends and psilocybin where legal. RTSL is unique in the MDI industry in that they do not use “full spectrum” oil or any other excipient not approved for human inhalation. RTSL’s MDI are made using FDA listed cans, valves, actuators, propellant and excipients.[1] RTSL uses no tetrahydrocannabinol (THC) in its products. RTSL is certified by CMDICB with respect to manufacturing of their MDI.

 

Everyday life involves dealing with anxiety. However, recent events have increased anxiety in the general population. For instance, according to the Anxiety and Depression Association of America (ADAA) the current coronavirus outbreak is triggering increased general anxiety disorder (GAD). https://adaa.org/finding-help/coronavirus-anxiety-helpful-resources.

 

Although RTSL makes no therapeutic claims about any of its proprietary blends of cannabinoids, a 2015 analysis of multiple studies concluded that cannabinoids including CBD is a promising treatment for numerous forms of anxiety, including social anxiety disorder (SAD), panic disorder, obsessive-compulsive disorder, GAD, and post-traumatic stress disorder (PTSD). (RTSL notes these studies although promising generally relied upon preclinical studies and not controlled clinical trials).

 

A National Center for Biotechnology Information published article stated – “Cannabinoids induce diverse responses on anxiety- and fear-related behaviors. Generally, low doses tend to induce anxiolytic-like effects, whereas high doses often cause the opposite. Inhibition of endocannabinoid degradation seems to circumvent these biphasic effects by enhancing CB1 receptor signaling in a temporarily and spatially restricted manner, thus reducing anxiety-like behaviors.” https://www.ncbi.nlm.nih.gov/pubmed/21309120. However, this article references THC which is anxiogenic and therefore not a good candidate for potential anxiety treatment modalities.

 

In contrast, “CBD given alone has anxiolytic properties, particularly under circumstances or in response to stimuli which normally provoke anxiety.” This makes cannabidiol (CBD) an attractive candidate for therapeutic treatment of anxiety and fear-related disorders.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486906/.

 

Although much additional research is needed, some clinical studies with humans have been promising in reduction of anxiety. Such studies clearly need additional testing related to dosing which involves pharmacokinetic oversight and control.

https://www.frontiersin.org/articles/10.3389/fpsyg.2019.02466/full

 

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

 

RTSL markets its MDI products directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders. RTSL currently does not sell any psilocybin products and is only testing pulmonary delivery geometry of its formulations with limited pre-clinical trials.

 

RTSL’s MDI can also be purchased online at www.rxoid.com.

 

We encourage all customers to do their own research regarding cannabinoids, the use of MDI’s and our products. RTSL makes no claims about therapeutic benefits of its products and they do not treat coronavirus in any manner. None of our products are intended to diagnose, treat, cure or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).

 

Visit RTSL online at www.rtslco.com.

 

*****

 

Forward-Looking Statements

 

This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

 

Contact:

Donal R. Schmidt, Jr.

Chief Executive Officer

investor@rtslco.com

 

Source:  Rapid Therapeutic Science Laboratories, Inc.

[1] DMF #’s are on file with RTSL.

Rapid Therapeutic Announces Its Plans to Utilize Its Proprietary Technology to Address Broad Applications for Delivery of Medications via the Pulmonary System to Focus on Addressable Markets of Over $7 Billion

Dallas, TX – April 20, 2020 – Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) (the “Company” or “RTSL”), a fully-reporting company with the U.S. Securities and Exchange Commission, is an innovative biotech company specializing in aerosol delivery of legal cannabinoids to the systemic blood stream though the pulmonary route of administration. RTSL manufactures white label products as well as its own branded metered dose inhalers (MDI) under the RxoidTM name using proprietary blends of pure cannabinoids and other generic drugs. RTSL cannabinoid formulas are legal for human consumption in Texas and many state and foreign countries. RTSL believes it is unique in the MDI industry in that they do not use “full spectrum” oil or any other product not approved for human inhalation. RTSL uses no THC in its products. RTSL is certified by the Cannabinoid MDI Certification Board (CMDICB, www.cmdicb.com) with respect to manufacturing of MDI.

 

RTSL CEO, Donal R. Schmidt, Jr. states the Covid-19 World-Wide Pandemic has sadly harmed many businesses; however, we continue to see strong demand for our existing product lines. Our primary business of manufacturing MDI with cannabinoid bases remains strong. We are moving ahead to formulate, manufacture and distribute new and unique formulations using our proprietary manufacturing processes.

 

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

 

RTSL markets its MDI products directly to pharmacies and physicians and select distributions chains.

 

RTSL’s MDI can also be purchased online at www.rxoid.com. RTSL makes no claims about therapeutic benefits of its products and they do not treat Coronavirus in any manner. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention.

 

Visit RTSL online at www.rtslco.com.

 

Statements contained in this press release with respect to the future are forward-looking statements. These statements reflect management’s reasonable judgment with respect to future events. Forward-looking statements involve risks and uncertainties. Forward-looking statements in this release include, without limitation, the continued demand for the Company’s products and the ability of the Company to formulate, manufacture and distribute new and unique formulations using its proprietary manufacturing processes. Actual results could differ materially from those anticipated as a result of various factors, including cyclical or other downturns in demand, significant pricing competition, unanticipated additions to industry capacity, and the timing and number of additional acquisitions made by the Company. Forward-looking statements are based on currently available information, and the Company assumes no obligation to update any such statements. A list of additional risk factors can be found in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission.

 

Donal R. Schmidt, Jr.
Chief Executive Officer
info@rtslco.com

Source: Rapid Therapeutic Science Laboratories, Inc.

About Rapid Therapeutic Science Laboratories


“Founded to find new ways to leverage cannabis in our daily lives”

 

Rapid Therapeutic Science Laboratories (RTSL) is focused on providing our customers with the most therapeutic and effective solutions in the cannabis space. We were founded to find new ways to leverage cannabis in our daily lives and effective delivery systems for those of us who wish to consume cannabis.

 

We believe in the highest quality cannabis and manufacturing practices to ensure that you get the purest possible product that is produced to CPMG compliance. Our team has spent almost 50 years in the cannabis space, and we have seen the benefits that cannabis has for people of all backgrounds and conditions.

 

RTSL was founded on the basis of aerosol manufacturing and we have developed unique technology and formulations to meet the needs of our customers looking for line extensions to their typical tinctures, gummies, and oils. We have also expanded to three additional areas of cannabis and cannabis production. Consulting with companies on everything from seeds to extraction and beyond, product development, hemp acquisitions.

 

Please take a deeper look at each of these offerings and reach out to us if we can be of service to your company or customers.


 

Therapeutic & Effective Cannabis Solutions – Product Development. Manufacturing. Consulting.

 


 

Rapid Therapeutic Science Laboratories (RTSL) is committed to continuous research, development, and delivery of new products in the cannabis space.

 

Consulting

 

With over 50 years of experience in the cannabis, pharmaceutical, consumer product and medical space, our team is uniquely positioned to help your business perform at the highest level possible.

 

Our goal is to help enhance your current strategy and product portfolio. We will meet with you to understand your business and needs and partner to ensure that we fill those to help you achieve peak performance.

 

Cannabis companies are rapidly developing, and we are here to help partner with you so that you don’t have to shoulder all of the load. Our consultants strive to ensure that anything that we bring to the table is actionable and tactically viable to deliver fast results to your business.

 


 

RTSL Products
Safe. Reliable. Effective. Fast-Acting.

RXoid
A Breakthrough Cannabis Device

 

Rxoid is our flagship product at this moment and is a breakthrough cannabis device.

 

Rxoid delivers 4 main benefits for the consumer:

 

1. Value
2. Safe, effective dosing
3. Quality ingredients (safest and best relief)
4. Fast acting

 

We believe you deserve natural, reliable and effective relief for what life throws at you.

 

We deliver the natural and effective relief you deserve in the exact dose you need.

 

The use of CBD is exploding across the US and the world and there are all kinds of stories and information about the therapeutic uses for it. We believe the key to safe and effective CBD use is to leverage the highest quality, natural CBD in the best delivery system. We have a wealth of experience in CBD, pharmaceutical and consumer goods and know that a quality delivery system can be the answer to providing effective relief. That is exactly what Rxoid has.

 

Our metered-dose inhaler delivers an accurate, effective and fast-acting dose of CBD directly to your lungs with every use.

 

Rxoid is manufactured using Current Good Manufacturing Practice (cGMP) that are mandated by the FDA with respect to the manufacture of all drugs and medical devices. This means we use the highest quality parts and manufacturing processes to ensure that Rxoid upholds a quality delivery system. It is important to do things to the proper standard in the CBD space and that is what we have set out to ensure.

 

Give our Rxoid MDI a try so that you can be confident in the fact that you are getting the natural and effective relief you deserve in every dose.

 

Source:  https://rtslco.com/

Disclaimer

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty six hundred dollars for Rapid Therapeutic Science Laboratories current news coverage by the company.  FNMG HOLDS NO SHARES OF Rapid Therapeutic Science Laboratories

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Sign Up & Get FREE News Alerts From FNM Today!